Resultados de la búsqueda 391-400 of 20285 for Two-phase

  1. Oncología (médica) - Ensayos clínicos

    ... phase. AZD0486 As Monotherapy In Participants With Relapsed/Refractory (R/R) ... two prior lines of therapies. The study has 2 Modules: Module 1 for FL and Module ...

  2. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    ... phase 2 dose (RP2D) of APG-2575. Understanding the Relationship Between Benign Breast Tissue, Benign Breast Disease, and Breast Cancer Development.

  3. Ensayos clínicos - Neurología

    The purpose of phase 2 of this trial is to evaluate the effectiveness of sequentially administering temozolomide and selinexor in recurrent glioblastoma as ...

  4. Oncología (médica) - Ensayos clínicos

    ... phase 2 dose (RP2D) of APG-2575. Understanding the Relationship Between Benign Breast Tissue, Benign Breast Disease, and Breast Cancer Development.

  5. Oncología (médica) - Ensayos clínicos

    ... phase 2 dose (RP2D) of APG-2575. Understanding the Relationship Between Benign Breast Tissue, Benign Breast Disease, and Breast Cancer Development.

  6. Oncología (médica) - Ensayos clínicos

    This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of AZD0486 monotherapy in adult participants with ...

  7. Clínica de las mamas - Ensayos clínicos - Mayo Clinic

    This is a phase 1b/2 study of the safety and efficacy of MLN0128 in combination with exemestane or fulvestrant therapy in women with estrogen receptor ...

  8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This is a randomized Phase 2 study of novel SEQUEnced immunotherapy (pembrolizumab) with anti-angiogenesis and chemotherapy in advanced gastric and ...

  9. Oncología (médica) - Ensayos clínicos

    ... phase 2 dose (RP2D) of APG-2575. Understanding the Relationship Between Benign Breast Tissue, Benign Breast Disease, and Breast Cancer Development.

  10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This is a phase 1b/2 study of the safety and efficacy of MLN0128 in combination with exemestane or fulvestrant therapy in women with estrogen receptor positive/ ...